Online inquiry

IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11691MR)

This product GTTS-WQ11691MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets influenza B virus hemagglutinin gene. The antibody can be applied in Influenza B infection research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NP_056660.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 956538
UniProt ID P03460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11691MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2651MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ3950MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ11889MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ15953MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ7942MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ12723MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ215MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ5824MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ChAglyCD
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW